XOMA Co. (NASDAQ:XOMA) CIO Bradley Sitko Purchases 4,134 Shares

XOMA Co. (NASDAQ:XOMA) CIO Bradley Sitko acquired 4,134 shares of XOMA stock in a transaction dated Friday, March 21st. The shares were bought at an average cost of $23.89 per share, for a total transaction of $98,761.26. Following the completion of the purchase, the executive now directly owns 10,484 shares of the company’s stock, valued at approximately $250,462.76. The trade was a 65.10 % increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

Bradley Sitko also recently made the following trade(s):

• On Wednesday, January 8th, Bradley Sitko purchased 313 shares of XOMA stock. The shares were bought at an average price of $25.60 per share, for a total transaction of $8,012.80.
• On Tuesday, December 31st, Bradley Sitko acquired 300 shares of XOMA stock. The stock was bought at an average price of $25.90 per share, with a total value of $7,770.00.

XOMA Trading Down 0.9 %

NASDAQ XOMA traded down $0.19 on Tuesday, hitting $20.74. The company’s stock had a trading volume of 29,881 shares, compared to its average volume of 26,515. The firm has a market cap of $248.44 million, a P/E ratio of -5.96 and a beta of 1.00. XOMA Co. has a 52-week low of $19.92 and a 52-week high of $35.00. The company’s 50-day simple moving average is $24.28 and its 200 day simple moving average is $27.08. The company has a current ratio of 7.52, a quick ratio of 7.52 and a debt-to-equity ratio of 1.28.

XOMA (NASDAQ:XOMA) last announced its quarterly earnings results on Monday, March 17th. The biotechnology company reported ($0.46) EPS for the quarter, missing analysts’ consensus estimates of ($0.29) by ($0.17). The business had revenue of $8.70 million during the quarter, compared to analysts’ expectations of $8.75 million. XOMA had a negative return on equity of 24.95% and a negative net margin of 151.34%. Research analysts predict that XOMA Co. will post -1.41 EPS for the current fiscal year.

Analyst Ratings Changes

XOMA has been the topic of several recent analyst reports. HC Wainwright restated a “buy” rating and issued a $104.00 target price on shares of XOMA in a report on Wednesday, March 19th. StockNews.com raised shares of XOMA from a “sell” rating to a “hold” rating in a report on Friday.

Hedge Funds Weigh In On XOMA

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Geode Capital Management LLC lifted its holdings in XOMA by 0.6% in the third quarter. Geode Capital Management LLC now owns 182,741 shares of the biotechnology company’s stock worth $4,840,000 after buying an additional 1,138 shares during the period. Barclays PLC raised its position in shares of XOMA by 300.7% in the 3rd quarter. Barclays PLC now owns 11,256 shares of the biotechnology company’s stock worth $298,000 after acquiring an additional 8,447 shares in the last quarter. BNP Paribas Financial Markets lifted its stake in shares of XOMA by 95.0% in the 3rd quarter. BNP Paribas Financial Markets now owns 1,632 shares of the biotechnology company’s stock valued at $43,000 after purchasing an additional 795 shares during the period. State Street Corp boosted its position in shares of XOMA by 1.2% during the third quarter. State Street Corp now owns 142,857 shares of the biotechnology company’s stock valued at $3,783,000 after purchasing an additional 1,754 shares in the last quarter. Finally, New York State Common Retirement Fund grew its stake in XOMA by 51.2% in the fourth quarter. New York State Common Retirement Fund now owns 2,362 shares of the biotechnology company’s stock worth $62,000 after purchasing an additional 800 shares during the period. Hedge funds and other institutional investors own 95.92% of the company’s stock.

XOMA Company Profile

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.